XTX Topco’s Arbutus Biopharma ABUS Stock Holding History

XTX Topco’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$180K	Buy	+40,021	New	+$175K	﹤0.01%	2882
2025 Q4	–	Sell	-11,364	Closed	-$51.6K	–	3258
2025 Q3	$51.6K	Sell	11,364 -12,550	-52%	-$46.1K	﹤0.01%	2160
2025 Q2	$73.9K	Sell	23,914 -48,498	-67%	-$161K	﹤0.01%	1938
2025 Q1	$253K	Buy	72,412 +19,831	+38%	+$66.1K	0.01%	1536
2024 Q4	$172K	Buy	52,581 +22,568	+75%	+$83K	0.01%	1614
2024 Q3	$116K	Buy	30,013 +12,975	+76%	+$49.8K	0.01%	1581
2024 Q2	$52.6K	Buy	+17,038	New	+$51.1K	﹤0.01%	1507
2022 Q4	–	Sell	-39,755	Closed	-$76K	–	1075
2022 Q3	$76K	Sell	39,755 -63,527	-62%	-$150K	0.02%	985
2022 Q2	$280K	Buy	103,282 +92,494	+857%	+$237K	0.11%	299
2022 Q1	$32K	Sell	10,788 -18,238	-63%	-$55.8K	0.01%	615
2021 Q4	$113K	Buy	29,026 +17,422	+150%	+$67.7K	0.06%	449
2021 Q3	$50K	Buy	+11,604	New	+$38.7K	0.02%	604

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

XTX Topco's ABUS Position: Q1 2026 in Review

XTX Topco opened a new position in Arbutus Biopharma (ABUS) in Q1 2026: 40,021 shares worth $180K. The stake represents ﹤0.01% of the portfolio and ranks #2882 among its holdings. This is a return to the name: XTX Topco previously reported a position in ABUS as recently as Q3 2025.

XTX Topco first reported a position in ABUS in Q3 2021 and has held it in 12 quarters since. The position peaked at $280K in Q2 2022. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

XTX Topco held 40,021 shares of Arbutus Biopharma worth $180K as of Q1 2026.
Arbutus Biopharma was a new XTX Topco position in Q1 2026.
Arbutus Biopharma made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #2882 holding.
XTX Topco first reported a position in Arbutus Biopharma in Q3 2021 and has held it in 12 quarters since.
XTX Topco's Arbutus Biopharma position peaked at $280K in Q2 2022.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.